Lugano, Switzerland, 18 September 2021 – The addition of immunotherapy to standard first-line treatment extends survival by eight months for patients with recurrent, persistent or metastatic cervical cancer, according to late breaking results from the KEYNOTE-826 study presented at the ESMO Congress 2021. (1)
Cervical cancer is a global problem, with more than 600,000 new cases and approximately 340,000 deaths in 2020. (2) In women aged 15 to 44 years, it is the second most frequent cancer and the second cause of cancer death.
Commenting on today’s results, Dr. Antonio González-Martín, Cancer Centre Director, Clínica Universidad de Navarra, Madrid, Spain said: “Patients with persistent,